ANTI-DCP2 (C-TERMINAL) ANTIBODY PRODUCED IN RABBIT AFFINITY ISOLATED ANTIBODY

General description

Dcp2 colocalizes with Dcp1 in distinct cytoplasmic foci along with other proteins involved in the 5′ to 3′ mRNA decay. These foci are termed PB (processing bodies) or DCP-bodies. hDCP2 contains a highly conserved Nudix (nucleoside diphosphate linked to an X moiety) motif critical for the decapping activity.

Immunogen

synthetic peptide corresponding to amino acids 406-420 of human DCP2, conjugated to KLH. The corresponding sequence is identical in rat and mouse.

Application

Anti-DCP2 (C-terminal) antibody has been used in immunocytochemistry and image correlation analysis. It may also be used in immunoblotting.

Anti-DCP2 antibody produced in rabbit is suitable for indirect immunofluorescence at a working concentration of 2-5μg/mL using paraformaldehyde-fixed NIH-3T3 cells over-expressing human DCP2 and western blot analysis at a working concentration of 2-4μg/mL using lysates of K-562 and Rat1 cells. Yale Center for High Throughput Cell Biology IF-tested antibodies. Each antibody is tested by immunofluorescence against HUVEC cells using the Yale HTCB IF protocol. To learn more about us and Yale Center for High Throughput Cell Biology partnership, visit sigma.com/htcb-if.

Biochem/physiol Actions

Dcp2 is an RNA binding protein and can cleave only a cap structure that is linked to an RNA moiety, suggesting that Dcp2 can differentially associate with specific mRNAs. Dcp2 cleaves the m7G mRNA cap in the 5′ to 3′ mRNA decay pathway, in association with Dcp1 and Hedls complex. Decapping is a critical and highly regulated step in the turnover of mRNA which involves decapping enzymes that hydrolyze the cap structure at the 5′ mRNA. Dcp2 is the catalytic subunit, and the mRNA is degraded by the major cytoplasmic 5′ to 3′ exonuclease XRN1. The enzymatic activity of DCP2 is critically dependent on the DCP1 subunit in vivo.

Target description

DCP2 (C-terminal) is a key component of an mRNA-decapping complex required for removal of the 5-prime cap from mRNA prior to its degradation from the 5-prime end.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Shipping Information:

Dry Ice Surcharge & Ice Pack Shipments: $40

More Information: https://cenmed.com/shipping-returns